期刊文献+

早期阿托伐他汀治疗对颅内动脉支架术前后患者C-反应蛋白的影响 被引量:1

Effect of Atorvastatin on C-reactive Protein Level at the Early Stage of Pre-/Post Stenting in Intracranial Artery
原文传递
导出
摘要 目的测定颅内支架术治疗前后患者C-反应蛋白(CRP)的水平,探讨阿托伐他汀对预防患者颅内支架再狭窄的可能性。方法将42例颅内支架患者随机分为对照组和治疗组(n=21)。对照组口服玻立维75mg+拜阿司匹林100mg,1次/d;治疗组口服阿托伐他汀40mg(术前7d开始)+玻立维75mg+拜阿司匹林100mg,1次/d。术前7d及1d,术后7d、3个月、6个月采用免疫透射比浊法分别测血清CRP水平。结果与对照组术前1d(7.44±0.73)mg/L、术后7d(27.61±1.81)mg/L、术后3个月(36.46±1.67)mg/L、术后6个月(26.84±0.76)mg/L比较,治疗组同期的CRP明显下降(P<0.05);与术后7d(12.05±0.55mg/L)比较,治疗组术前1d(6.22±0.57)mg/L、术后3个月(6.03±0.46)mg/L、6个月(6.12±0.77)mg/L下降明显(P<0.01);术前1d、术后3个月、6个月之间差异无统计学意义(P>0.05)。结论阿托伐他汀可有效抑制炎症因子,是预防支架内再狭窄的有效治疗方法之一。 Objective To investigate influence of C-reactive protein levele on pre-/post stent in intracranial artery treated with atorvastatin at the early stage. Method 42 patients treated with stent in intracranial artery were randomly divided into 2 groups: control group(n=21 ) receive plavix 75mg + aspirin enteric-coated tablet 100mg per day, treatment group(n=21) receive atorvastatin 40 mg(begining at day 7 pre-stenting) + plavix 75 mg + aspirin enteric-coated tablet 100mg per day. C-reactive protein level was examined at 7 d, and 1d before stenting and at 7d, 3 month, and 6 month after stenting with immunological transmission turbidimetry. Result Compared with control group C-reactive protein level at 1 day pre-stenting(7.44±0.73)mg/L, at 7 day post-stenting (27.61±1.81) mg/L, at 3 month post-stenting (36.46±1.67)mg/L, and at 6 month post-stenting (26.84±0.76)mg/L were significantly lower in treatment group(P〈0.05). Compared with the same period, C-reactive protein level was significantly higher in treatment group at 7 day post-stenting (12.05±0.55)mg/L. Compared with that in treatment group at 1 day prestenting(6.22±0.57)mg/L, at 3 month post-stenting(6.03±0.46)mg/L, and at 6 month post-stenting(6.12±0.77) mg/L,P〈0.01. There was no significant difference between day 1 pre-stenting, 3 month post-stenting,6 month poststenting(P〉0.05). Conclusion The therapy with atorvastatin turned out to be efficient to inhibit inflammatory factor and prevent stent restenosis.
出处 《热带医学杂志》 CAS 2010年第4期426-428,共3页 Journal of Tropical Medicine
关键词 支架 C反应蛋白 阿托伐他汀 stent C-reactive protein atorvastatin
  • 相关文献

参考文献20

  • 1Mitra AK,Agrawal DK.In stent restenosis:bane of the stent era [ J ] .J Clin Pathol, 2006,59 ( 3 ) : 232-239.
  • 2Hong YJ,Jeong MH,Lim SY,et al.Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting [ J ]. Circ J, 2005,69 (12) : 1477-1483.
  • 3Yip HK,Hung WC,Yang CH,et al.Serum concentrations of high -sensitivityC -reactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery steuting [ J ].Circ J, 2005,69(10) : 1202-1207.
  • 4Chan AW, Bhatt DL, Chew DP, et al.Relation of inflammation and benefit of statins after percutaneous coronary internventions[J]. Circulation, 2003,107( 13): 1750-1756.
  • 5Slevin M, Krupinski J.A role for monomeric C-reactive protein in regulation of angiogenesis, endothelial cell inflammation and thrombus formation in cardiovascular/cerebrovascular disease [ J ]. Histol Histopathol, 2009,24 ( 11 ) : 1473-1478.
  • 6MASERI A.Inflammation,atherosclerosis and ischemic events exploring the hidden side of the moon [J].N Engl J Med, 2007,336(14) : 1014-1016.
  • 7Blake GJ,Ridker PM.Novel clinical markers of vascular wall inflammation[J].Cire Res,2001,89(9) :763-771.
  • 8Boulman N,Levy Y,Eeiba R,et al.Inceased C-reactive protein levels in the poiyeystic coronary syndrome : a marker of cardiovascular disease [J].Clin Endocrinol Metab, 2004,89 ( 5 ) : 2160-2165.
  • 9Zacho J,Tybjaerg-Hansen A,Nordestgaard BG.C-reactive protein, genetically elevated levels and risk of ischemic heart and cerebrovascular disease [J].Scand J Clin Lab Invest, 2009,69 ( 4 ) : 442 -446.
  • 10张旭,江秀龙,雷惠新.脑梗死患者血清超敏C反应蛋白检测及临床意义[J].疑难病杂志,2008,7(2):71-73. 被引量:27

二级参考文献28

  • 1李辉,王兆宏.血清C反应蛋白在急性脑梗死患者临床评估中的价值[J].疑难病杂志,2006,5(2):97-99. 被引量:12
  • 2各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33022
  • 3Carroll BA. Carotid sonography[J]. Radiology,1991,178:303-313.
  • 4Chiadoni L, Taddei S, Virds A, et al. Endothelial function and common carotid artery wall thickening in patients with essential hypertension[J]. Hypertension, 1998, 32:25-29.
  • 5Touboul PJ, Elbaz A, KoUer C, et al. Conmxm carotid artery intimamedia thickness and brain infarction : the Etude du Profil Genetique de 1'Infaretus Cerebral (GENIC) case-control study. The GENIC Investigators[J] . Circulation, 2000, 102: 313-318.
  • 6Fourcelot L, Tranquart F, Bray JM. Ultrosound characterization and quantification of carotid atherosclerosis lesions [ J ] . Minerva Cardioangiol, 1999, 47: 15-24.
  • 7Aburahma AF, Kyer PD, Robinson PA, et al. The correlation of ultrasonic carotid plaque morphology and carotid plaque hemorrhage: clinical implications[J]. Surgery, 1998, 124:721-726.
  • 8Braganza DM, Bennett MR. New insights into atherosclerotic plaque rupture [J]. Postgrad Med J,2001,77:94-98.
  • 9Heart protection study collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals:a randomized placebo-controlled trial. Lancet ,2002:360:7-22.
  • 10Perdersen TR. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease :the Scandinavian simvastatin Survival Study (4S). Lancet ,1994,344:1383-1389.

共引文献89

同被引文献16

  • 1Higashi Y,Noma K,Yoshizumi M,et al.Endothelial function and oxidative stress in cardiovascular diseases [J].Circ J,2009, 73(3) :411-418.
  • 2Cai H,Harrison DG.Endothelial dysfunction in cardiovascular diseases : the role of oxidant stress [ J ].Circ Res, 2000,87 (10) : 840- 844.
  • 3Singh U, Jialal I.Oxidant stress and atherosclerosis [ J ]. Pathophysiology, 2006,13 ( 3 ) : 129-142.
  • 4Kastrati A, Mehilli J, Beckerath N von, et al.Simlimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis [ J ] .JAMA, 2005,293 (2) : 165-171.
  • 5Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J].N Engl J Med, 2003,349(14) : 1315-1323.
  • 6Park J, Ha H, Ahn HJ, et al.Sirolimus inhibits platelet-derived growth factor-induced collagen synthesis in rat vascular smooth muscle cells [ J].Transplant Proc ; 2005,37 ( 8 ) : 3459-3462.
  • 7Wassmann S, Laufs U, Muller K, et al.Cellular antioxidant effects of atorvastatin in vitro and in vivo [J].Arterioscler Thromb Vasc Biol, 2002,22 ( 2 ) : 300-305.
  • 8Camici GG,Steffel J,Akhmedov A,et al.Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation:a potential treatment strategy for drug-eluting stents [ J ] .Circulation, 2006,114 (14) : 1512-1521.
  • 9Kavurma MM,Figg N,Bennett MR,et al.Oxidative stress regulates IGF1R expression in vascular smooth muscle cells via p53 and HDAC recruitment [ J ].Biochem J, 2007,407 ( 1 ) : 79- 87.
  • 10Erl W,Hristov M,Neureuter M,et al.HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle ceils [ J ] .Atherosclerosis, 2003,169 (2) : 251-258.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部